![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Concentration-QT Analysis of Firsocostat,
a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Chia-Hsiang Hsueh, Mun Sang Yue, Victoria Millward, Darren Huber, Chuhan Chung, Robert P. Myers, Elijah Weber, Cara Nelson - Gilead Sciences, Inc., Foster City, California, USA
![0915201](../images/091520/091520-2/0915201.gif)
![0915202](../images/091520/091520-2/0915202.gif)
![0915203](../images/091520/091520-2/0915203.gif)
References: 1. Lawitz EJ, et al. Clin Gastroenterol Hepatol 2018;16:1983-91; 2. Loomba R, et al. Gastroenterology 2018;155:1463-73; 3. US Food & Drug Administration. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Oct 2012; 4. Westlin WF, et al. EASL 2016, oral FRI-355; 5. Garnett C, et al. J Pharmacokinet Pharmacodyn 2018;45:383-97.
Acknowledgments: We extend our thanks to the subjects for their participation in this study. This study was funded by Gilead Sciences, Inc.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|